Compare Matson Inc (MATX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Tango Therapeutics Inc. — how do they compare? Matson Inc trades at $235.22 (market cap $7.04B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Matson Inc is the larger of the two by market cap, and Matson Inc pays a 0.65% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 25 Days and Tango Therapeutics Inc. for 0 Days on average.
| MATX | TNGX | |
|---|---|---|
Market Cap | $7.04B | $3.74B |
Volume | 295,660 | 3,438,781 |
Sector | Industrials | Health |
52-Week High | $238.60 | $32.90 |
52-Week Low | $93.22 | $7.50 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $7.64B | $2.76B |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $235.22, up 3.31% with strong bullish momentum supported by consistent earnings beats and positive technical indicators. The stock shows robust fundamentals with a 13.41% net income margin and 17.21% ROE, while valuation metrics remain reasonable with a P/E of 15.87. Recent Q2 2026 results exceeded expectations with EPS of $4.27 versus $3.79 expected, driving positive sentiment.
Outlook remains positive with Wall Street analysts projecting 27.3% upside potential and strong institutional buying activity. Key risks include freight market volatility and competitive pressures, but the company's raised full-year guidance and dividend payments provide stability for investors seeking transportation sector exposure.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
